Rashmi Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rashmi Sharma has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
Summaya Perveen
Infectious Diseases Division
11 shared publicationsAnjali Negi
Infectious Diseases Division
7 shared publicationsSapna Saini
Infectious Diseases Division, CSIR - Indian Institute of Integrative Medicine, Jammu 180001, India
7 shared publicationsAnjali Gangwar
Infectious Diseases Division, CSIR - Indian Institute of Integrative Medicine, Jammu 180001, India
6 shared publicationsSunny Pal
Infectious Diseases Division
3 shared publicationsHarpreet Kour
Natural Products and Medicinal Chemistry
2 shared publications
Latest Publications
- 9 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 279
Self-emulsifying Delivery System for Improving Biopharmaceutical Performance of a Novel Antitubercular Agent: Formulation Development, Biological Activity and Pharmacokinetic Evaluation
A nitroimidazole-derived lead (IIIM-019) was developed as a part of our institutional drug discovery program in the area of tuberculosis. This molecule suf
- 9 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 279
Self-emulsifying Delivery System for Improving Biopharmaceutical Performance of a Novel Antitubercular Agent: Formulation Development, Biological Activity and Pharmacokinetic Evaluation
A nitroimidazole-derived lead (IIIM-019) was developed as a part of our institutional drug discovery program in the area of tuberculosis. This molecule suf
- 14 July 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Total Synthesis and Antibacterial Evaluation of (-)- and (+)-epi-Perrottetinene.
Antimicrobial resistance (AMR) is a critical threat to global public health, with emerging resistance to Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), often referred to as a silent pandemic. Despite ongoing efforts in the fight against AMR, the drug discovery pipeline remains underdeveloped, highlighting the urgent need to explore natural and synthetic approaches. Cannabinoid-inspired natural products represent an underexplored chemical space with antimicrobial potential. Herein, we report an efficient, scalable, and enantioselective synthesis and antimicrobial evaluation of epi-perrottetinene (epi-PET), an unnatural bibenzyl-based cannabinoid analog of liverwort-derived perrottetinene. The synthetic strategy employs inexpensive starting materials and a Lewis acid-mediated Friedel-Crafts cyclization to enable regioselective access to both Δ8- and Δ9-epi-PET isomers. Biological evaluation revealed potent antibacterial activity against Gram-positive pathogens, with particularly strong efficacy against drug-sensitive and drug-resistant S. aureus strains, including MRSA clinical isolates. Notably, the lead compound E exhibited remarkable activity, with MIC values ≤ 1.2 μg/mL. Compound E remained effective against efflux pump-overexpressing strains and bacterial biofilms and eradicated intracellular bacteria, while displaying low hemolytic activity (3.4% of rabbit erythrocytes) and minimal cytotoxicity toward mammalian cell lines (N2a and RAW). Mechanistic studies indicate that bacterial membrane disruption is a key contributor to the observed bactericidal activity, consistent with rapid killing and a low propensity for resistance development. The work establishes epi-perrottetinene as a promising cannabinoid-inspired antibacterial scaffold and highlights the potential of nonclassical cannabinoids as a source of new chemical matter for addressing antimicrobial resistance.
- 14 July 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Total Synthesis and Antibacterial Evaluation of (-)- and (+)-epi-Perrottetinene.
Antimicrobial resistance (AMR) is a critical threat to global public health, with emerging resistance to Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), often referred to as a silent pandemic. Despite ongoing efforts in the fight against AMR, the drug discovery pipeline remains underdeveloped, highlighting the urgent need to explore natural and synthetic approaches. Cannabinoid-inspired natural products represent an underexplored chemical space with antimicrobial potential. Herein, we report an efficient, scalable, and enantioselective synthesis and antimicrobial evaluation of epi-perrottetinene (epi-PET), an unnatural bibenzyl-based cannabinoid analog of liverwort-derived perrottetinene. The synthetic strategy employs inexpensive starting materials and a Lewis acid-mediated Friedel-Crafts cyclization to enable regioselective access to both Δ8- and Δ9-epi-PET isomers. Biological evaluation revealed potent antibacterial activity against Gram-positive pathogens, with particularly strong efficacy against drug-sensitive and drug-resistant S. aureus strains, including MRSA clinical isolates. Notably, the lead compound E exhibited remarkable activity, with MIC values ≤ 1.2 μg/mL. Compound E remained effective against efflux pump-overexpressing strains and bacterial biofilms and eradicated intracellular bacteria, while displaying low hemolytic activity (3.4% of rabbit erythrocytes) and minimal cytotoxicity toward mammalian cell lines (N2a and RAW). Mechanistic studies indicate that bacterial membrane disruption is a key contributor to the observed bactericidal activity, consistent with rapid killing and a low propensity for resistance development. The work establishes epi-perrottetinene as a promising cannabinoid-inspired antibacterial scaffold and highlights the potential of nonclassical cannabinoids as a source of new chemical matter for addressing antimicrobial resistance.
- 10 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18178-18196
Keeping Up with the Q’s: Mechanistic Insights and Validation of Quinoline and Quinazoline Scaffolds as Potent Drugs against Tuberculosis
The eternal battle against Tuberculosis necessitates the discovery of novel drugs. This study outlines identification of novel quinoline and quinazoline series through phenotypic screening of the ChemDiv library against Mtb-H37Rv. The potency, mode of inhibition, and structure-activity relationships around the confirmed actives are described. Both series disclosed potent anti-TB activity against drug-sensitive and drug-resistant strains. The quinazoline series exhibited cytotoxicity toward eukaryotic cells, while the quinoline compounds were both active and noncytotoxic. Among the quinoline compounds, the most promising molecule, IIIM-IDD-Q1b, exhibited an IC90 of 9.7 μg/mL, with no observed cytotoxicity, resulting in a high safety index (>10). It demonstrated potent intracellular inhibition against Mtb as made evident by fluorescence imaging and CFU enumeration. Mode-of-action studies revealed that quinoline compounds target DNA gyrase, while quinazoline series target ATP synthase. Overall, both series demonstrate promising biological properties and a favorable pharmacokinetic profile. Further medicinal chemistry optimization could enhance and boost the anti-TB potency of the identified compounds.
- 10 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18178-18196
Keeping Up with the Q’s: Mechanistic Insights and Validation of Quinoline and Quinazoline Scaffolds as Potent Drugs against Tuberculosis
The eternal battle against Tuberculosis necessitates the discovery of novel drugs. This study outlines identification of novel quinoline and quinazoline series through phenotypic screening of the ChemDiv library against Mtb-H37Rv. The potency, mode of inhibition, and structure-activity relationships around the confirmed actives are described. Both series disclosed potent anti-TB activity against drug-sensitive and drug-resistant strains. The quinazoline series exhibited cytotoxicity toward eukaryotic cells, while the quinoline compounds were both active and noncytotoxic. Among the quinoline compounds, the most promising molecule, IIIM-IDD-Q1b, exhibited an IC90 of 9.7 μg/mL, with no observed cytotoxicity, resulting in a high safety index (>10). It demonstrated potent intracellular inhibition against Mtb as made evident by fluorescence imaging and CFU enumeration. Mode-of-action studies revealed that quinoline compounds target DNA gyrase, while quinazoline series target ATP synthase. Overall, both series demonstrate promising biological properties and a favorable pharmacokinetic profile. Further medicinal chemistry optimization could enhance and boost the anti-TB potency of the identified compounds.
- 9 May 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Galectins as Drivers of Host–Pathogen Dynamics in Mycobacterium tuberculosis Infection
Galectins form a protein family with a conserved carbohydrate-binding domain that specifically interacts with β-galactoside-containing glycoconjugates, which are found abundantly on mammalian cell surfaces. These proteins play crucial roles in various physiological and pathological processes including immune responses, cell adhesion, inflammation, and apoptosis. During tuberculosis infection, galectins exert diverse impacts on pathogenesis. The interaction between host and pathogen during TB involves intricate mechanisms influencing disease outcomes, where the pathogen exploits host glycosylation patterns to evade immune detection, underscoring the significant role of galectins in regulating these crucial host-pathogen interactions. Galectins facilitate pathogen recognition, enhance the phagocytosis of mycobacteria, support the formation of granuloma, and carefully balance the protective immunity against potential tissue damage. Additionally, galectins have an impact on the cytokine milieu by regulating the levels of pro-inflammatory cytokines and chemokines, essential for orchestrating granuloma formation and maintaining tuberculosis-associated homeostasis. This review delves into the intricate connection between galectins and tuberculosis; uncovering essential molecular mechanisms that deepen our understanding of how these proteins contribute to combating this pervasive infectious disease. Here we discuss the multifaceted roles that galectins play to uniquely and critically influence the core dynamics of host-pathogen interactions in tuberculosis.
- 9 May 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
Galectins as Drivers of Host–Pathogen Dynamics in Mycobacterium tuberculosis Infection
Galectins form a protein family with a conserved carbohydrate-binding domain that specifically interacts with β-galactoside-containing glycoconjugates, which are found abundantly on mammalian cell surfaces. These proteins play crucial roles in various physiological and pathological processes including immune responses, cell adhesion, inflammation, and apoptosis. During tuberculosis infection, galectins exert diverse impacts on pathogenesis. The interaction between host and pathogen during TB involves intricate mechanisms influencing disease outcomes, where the pathogen exploits host glycosylation patterns to evade immune detection, underscoring the significant role of galectins in regulating these crucial host-pathogen interactions. Galectins facilitate pathogen recognition, enhance the phagocytosis of mycobacteria, support the formation of granuloma, and carefully balance the protective immunity against potential tissue damage. Additionally, galectins have an impact on the cytokine milieu by regulating the levels of pro-inflammatory cytokines and chemokines, essential for orchestrating granuloma formation and maintaining tuberculosis-associated homeostasis. This review delves into the intricate connection between galectins and tuberculosis; uncovering essential molecular mechanisms that deepen our understanding of how these proteins contribute to combating this pervasive infectious disease. Here we discuss the multifaceted roles that galectins play to uniquely and critically influence the core dynamics of host-pathogen interactions in tuberculosis.
- 28 January 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (2) , 350-365
Decoding the Role of Antimicrobial Peptides in the Fight against Mycobacterium tuberculosis
Tuberculosis (TB), a leading infectious disease caused by the pathogen Mycobacterium tuberculosis, poses a significant treatment challenge due to its unique characteristics and resistance to existing drugs. The conventional treatment regimens, which are lengthy and involve multiple drugs, often result in poor patient adherence and subsequent drug resistance, particularly with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. This highlights the urgent need for novel anti-TB therapies and new drug targets. Antimicrobial peptides (AMPs), which are natural host defense molecules present in all living organisms, offer a promising alternative to traditional small-molecule drugs. AMPs have several advantages, including their broad-spectrum activity and the potential to circumvent existing resistance mechanisms. However, their clinical application faces challenges such as stability, delivery, and potential toxicity. This review aims to provide essential information on AMPs, including their sources, classification, mode of action, induction within the host under stress, efficacy against M. tuberculosis, clinical status and hurdles to their use. It also highlights future research directions to address these challenges and advance the development of AMP-based therapies for TB.
- 28 January 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (2) , 350-365
Decoding the Role of Antimicrobial Peptides in the Fight against Mycobacterium tuberculosis
Tuberculosis (TB), a leading infectious disease caused by the pathogen Mycobacterium tuberculosis, poses a significant treatment challenge due to its unique characteristics and resistance to existing drugs. The conventional treatment regimens, which are lengthy and involve multiple drugs, often result in poor patient adherence and subsequent drug resistance, particularly with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. This highlights the urgent need for novel anti-TB therapies and new drug targets. Antimicrobial peptides (AMPs), which are natural host defense molecules present in all living organisms, offer a promising alternative to traditional small-molecule drugs. AMPs have several advantages, including their broad-spectrum activity and the potential to circumvent existing resistance mechanisms. However, their clinical application faces challenges such as stability, delivery, and potential toxicity. This review aims to provide essential information on AMPs, including their sources, classification, mode of action, induction within the host under stress, efficacy against M. tuberculosis, clinical status and hurdles to their use. It also highlights future research directions to address these challenges and advance the development of AMP-based therapies for TB.
- 8 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (4) , 1476-1498
Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target
Inhibitors of mycobacterial ATP synthase, such as bedaquiline, TBAJ-587, TBAJ-876, squaramides, GaMF1, and DeMF1, break the energy metabolism and effectively inhibit Mtb, offering promising strategies against mycobacterial infections.
- 8 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (4) , 1476-1498
Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target
Inhibitors of mycobacterial ATP synthase, such as bedaquiline, TBAJ-587, TBAJ-876, squaramides, GaMF1, and DeMF1, break the energy metabolism and effectively inhibit Mtb, offering promising strategies against mycobacterial infections.
- 26 December 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (3) , 1304-1328
Discovery and biological evaluation of nitrofuranyl–pyrazolopyrimidine hybrid conjugates as potent antimicrobial agents targeting Staphylococcus aureus and methicillin-resistant S. aureus
Nitrofuranyl–pyrazolopyrimidine conjugates exhibiting potent in vitro and in vivo efficacy against Gram-positive bacterial strain S. aureus and its resistant variant methicillin-resistant S. aureus.
- 26 December 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (3) , 1304-1328
Discovery and biological evaluation of nitrofuranyl–pyrazolopyrimidine hybrid conjugates as potent antimicrobial agents targeting Staphylococcus aureus and methicillin-resistant S. aureus
Nitrofuranyl–pyrazolopyrimidine conjugates exhibiting potent in vitro and in vivo efficacy against Gram-positive bacterial strain S. aureus and its resistant variant methicillin-resistant S. aureus.
- Open Access
- 17 October 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (45) , 32771-32785
Antibacterial activity of structurally diverse natural prenylated isobavachalcone derivatives
Isobavachalcone (IBC) is a natural prenylated flavonoid containing chalcone and prenyl chain moieties with a wide range of biological and pharmacological properties. In this work, we synthesized structurally diversified derivatives (IBC-2 to IBC-10) from the natural prenylated chalcone IBC isolated from Psoralea corylifolia and assessed their antibacterial potency against the Gram-positive and Gram-negative bacterial strains S. aureus ATCC 29213, MRSA ATCC 15187, E. coli ATCC25922 and P. aeruginosa ATCC 27853. IBC and IBC-2 exhibited a minimum inhibition concentration (MIC) of 5.0 μM against S. aureus ATCC 29213, whereas IBC-3 exhibited a broad-spectrum activity against Gram-positive and Gram-negative pathogens. Cytotoxicity assessments on the murine RAW 264.7 macrophage cell line revealed minimal to moderate cytotoxicity for IBC-2 and IBC-3 with a favorable selectivity index (>10). Time- and concentration-dependent studies further supported the bactericidal nature of the compounds, as IBC, IBC-2, and IBC-3 exhibited concentration-dependent killing of S. aureus in a time-dependent manner. Furthermore, combination studies, SEM analysis, and PI staining suggest that IBC-3's mechanism of action targets the bacteria's cytoplasmic membrane or cell wall. The bioactive compounds displayed promising drug-like characteristics and a favorable pharmacokinetic profile (ADME-Tox), indicating a projected high oral bioavailability. Structure–activity relationships (SARs) drawn from this study reveal that a prenyl chain at the A-ring and hydroxy functional groups attached to the aromatic rings of chalcone scaffolds are responsible for this antibacterial potential, which will be helpful in the future discovery and development of antibiotics from natural products to overcome the antibiotic resistance crisis.
- 17 October 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (45) , 32771-32785
Open AccessAntibacterial activity of structurally diverse natural prenylated isobavachalcone derivatives
Isobavachalcone (IBC) is a natural prenylated flavonoid containing chalcone and prenyl chain moieties with a wide range of biological and pharmacological properties. In this work, we synthesized structurally diversified derivatives (IBC-2 to IBC-10) from the natural prenylated chalcone IBC isolated from Psoralea corylifolia and assessed their antibacterial potency against the Gram-positive and Gram-negative bacterial strains S. aureus ATCC 29213, MRSA ATCC 15187, E. coli ATCC25922 and P. aeruginosa ATCC 27853. IBC and IBC-2 exhibited a minimum inhibition concentration (MIC) of 5.0 μM against S. aureus ATCC 29213, whereas IBC-3 exhibited a broad-spectrum activity against Gram-positive and Gram-negative pathogens. Cytotoxicity assessments on the murine RAW 264.7 macrophage cell line revealed minimal to moderate cytotoxicity for IBC-2 and IBC-3 with a favorable selectivity index (>10). Time- and concentration-dependent studies further supported the bactericidal nature of the compounds, as IBC, IBC-2, and IBC-3 exhibited concentration-dependent killing of S. aureus in a time-dependent manner. Furthermore, combination studies, SEM analysis, and PI staining suggest that IBC-3's mechanism of action targets the bacteria's cytoplasmic membrane or cell wall. The bioactive compounds displayed promising drug-like characteristics and a favorable pharmacokinetic profile (ADME-Tox), indicating a projected high oral bioavailability. Structure–activity relationships (SARs) drawn from this study reveal that a prenyl chain at the A-ring and hydroxy functional groups attached to the aromatic rings of chalcone scaffolds are responsible for this antibacterial potential, which will be helpful in the future discovery and development of antibiotics from natural products to overcome the antibiotic resistance crisis.
- 7 August 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 151, 107702
N-Acyl phenothiazines as mycobacterial ATP synthase inhibitors: Rational design, synthesis and in vitro evaluation against drug sensitive, RR and MDR-TB
- 7 August 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 151, 107702
N-Acyl phenothiazines as mycobacterial ATP synthase inhibitors: Rational design, synthesis and in vitro evaluation against drug sensitive, RR and MDR-TB
- 14 February 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (4) , 2264-2286
Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid
Delamanid, bedaquiline, and pretomanid have been recently added in the anti-tuberculosis (anti-TB) treatment regimens and have emerged as potential solutions for combating drug-resistant TB. These drugs have proven to be effective in treating drug-resistant TB when used in combination. However, concerns have been raised about the eventual loss of these drugs due to evolving resistance mechanisms and certain adverse effects such as prolonged QT period, gastrointestinal problems, hepatotoxicity, and renal disorders. This Perspective emphasizes the properties of these first-in-class drugs, including their mechanism of action, pharmacokinetics/pharmacodynamics profiles, clinical studies, adverse events, and underlying resistance mechanisms. A brief coverage of efforts toward the generation of best-in-class leads in each class is also provided. The ongoing clinical trials of new combinations of these drugs are discussed, thus providing a better insight into the use of these drugs while designing an effective treatment regimen for resistant TB cases.
- 14 February 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (4) , 2264-2286
Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid
Delamanid, bedaquiline, and pretomanid have been recently added in the anti-tuberculosis (anti-TB) treatment regimens and have emerged as potential solutions for combating drug-resistant TB. These drugs have proven to be effective in treating drug-resistant TB when used in combination. However, concerns have been raised about the eventual loss of these drugs due to evolving resistance mechanisms and certain adverse effects such as prolonged QT period, gastrointestinal problems, hepatotoxicity, and renal disorders. This Perspective emphasizes the properties of these first-in-class drugs, including their mechanism of action, pharmacokinetics/pharmacodynamics profiles, clinical studies, adverse events, and underlying resistance mechanisms. A brief coverage of efforts toward the generation of best-in-class leads in each class is also provided. The ongoing clinical trials of new combinations of these drugs are discussed, thus providing a better insight into the use of these drugs while designing an effective treatment regimen for resistant TB cases.